Targeting IL-4 receptors can address so-called Th2-mediated skin inflammation – a mechanism that the drug shares with Sanofi and Regeneron’s blockbuster AD therapy Dupixent (dupilumab ...

For example, a growing number of allergic patients (e.g., asthma, atopic dermatitis) are being treated with biologics that block the IL-4/IL-13 axis (e.g., dupilumab, an anti-IL-4Rα mAb) (82, 120).

Pemphigus encompasses a heterogeneous group of autoimmune blistering diseases, which affect both mucous membranes and the skin. The disease usually runs a chronic-relapsing course, with a potentially ...